ABSTRACT
Background and objective Lower limb varicose veins are very prevalent and there are several treatment options available, including conventional surgery and polidocanol foam sclerotherapy. Few studies analyze therapeutic modalities based on PROMs (patient-reported outcome measures). The aim of this study was to evaluate the impact of treatment with polidocanol foam sclerotherapy compared to conventional surgery in a large sample, based on an analysis of PROMs.
Methods This was a prospective, observational, and qualitative study of 205 patients who underwent varicose vein treatment with polidocanol foam sclerotherapy (57 patients - 90 legs) or conventional surgery (148 patients - 236 legs). Patients were assessed preoperatively and 30 days after the procedure using venous disease severity scores (VCSS) and specific venous disease quality of life questionnaires (VEINES-QoL/Sym).
Results Both treatments promoted a significant improvement in VCSS and VEINES 30 days after the procedure (p < 0.05). However, surgery promoted a greater improvement in VCSS (on average 4.02 points difference, p < 0.001), VEINES-QoL (8 points difference, p < 0.001) and VEINES-Sym (on average 11.66 points better, p < 0.001) compared to sclerotherapy. Post-operative pain and aesthetic concern about the legs were the domains of the questionnaires that had the greatest impact on this difference between the two types of treatment, generating worse results with sclerotherapy.
Conclusion Polidocanol foam sclerotherapy and conventional surgery have a positive impact on quality of life after 30 days, but there is a more significant improvement in patients undergoing conventional surgery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Hospital Israelita Albert Einstein gave ethical approval for this work (protocols: CAAE 51668821.6.0000.0071 and 51668821.6.3001.0083).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interest: none.
Financial disclosures: none.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
